Patents by Inventor Alexis Nahama

Alexis Nahama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230270713
    Abstract: Disclosed herein are methods of administering resiniferatoxin (RTX) intravesically for treatment of bladder pain, and compositions for use in such methods.
    Type: Application
    Filed: June 18, 2021
    Publication date: August 31, 2023
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Alexis Nahama, Henry Hongjun Ji
  • Publication number: 20230143545
    Abstract: There is disclosed a method for treating pulmonary inflammatory disease comprising administering an effective amount of resiniferatoxin (RTX) by an epidural, peri-ganglionic or intra-ganglionic administration. In some embodiments, the dose of RTX for an adult human is from about 0.1 ?g to about 100 ?g.
    Type: Application
    Filed: March 12, 2021
    Publication date: May 11, 2023
    Applicant: Board of Regents of the University of Nebraska
    Inventors: Alexis Nahama, Henry Hongjun Ji, Irving H. Zucker, Hanjun Wang
  • Publication number: 20220096428
    Abstract: Disclosed herein are methods of administering resiniferatoxin (RTX) for treatment of osteoarthritis (OA) pain, and compositions for use in such methods.
    Type: Application
    Filed: January 21, 2020
    Publication date: March 31, 2022
    Inventors: Alexis Nahama, Henry Hongjun Ji
  • Publication number: 20210393515
    Abstract: Disclosed herein are methods of administering resiniferatoxin (RTX) perineurally for treatment of maladaptive pain, and compositions for use in such methods.
    Type: Application
    Filed: June 11, 2021
    Publication date: December 23, 2021
    Applicant: Sorrento Therapeutics, Inc.
    Inventor: Alexis Nahama
  • Publication number: 20210299090
    Abstract: There is disclosed a method for treating Parkinson's Disease (PD) comprising administering an effective amount of Resiniferatoxin (RTX) by an intrathecal or intracisternal administration. In some embodiments, the dose of RTX for an adult human is from about 0.1 ?g to about 100 ?g.
    Type: Application
    Filed: June 11, 2021
    Publication date: September 30, 2021
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Alexis Nahama, Henry Hongjun Ji